자궁내막암 시장 규모, 점유율, 성장 분석 : 암 유형별, 치료별, 진단 방법별, 단계별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Global Endometrial Cancer Market size was valued at USD 30.1 Billion in 2024 and is poised to grow from USD 31.57 Billion in 2025 to USD 46.3 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The global endometrial cancer market is experiencing robust growth driven by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic methods, particularly molecular profiling and genetic testing, facilitate accurate and personalized treatment strategies. The emergence of targeted therapies, immunotherapies, and combination treatment approaches contributes to market expansion by improving efficacy and minimizing adverse effects compared to conventional treatments. Furthermore, advancements like genomic profiling and liquid biopsies support early detection efforts and customized therapy options. Nevertheless, obstacles such as high treatment costs, limited access to advanced healthcare facilities, and the necessity for effective early detection techniques pose significant challenges that must be addressed to alleviate the global endometrial cancer burden.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segments Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

A significant factor propelling the global endometrial cancer market is the rising incidence of endometrial cancer across the globe. As one of the most prevalent gynecological cancers, its occurrence is on the upswing, largely due to a combination of risk factors like obesity, hormonal fluctuations, and diabetes. This surge in cases highlights the urgent need for advanced diagnostic and treatment options, boosting the market's expansion. As awareness regarding endometrial cancer grows and the demand for effective healthcare solutions increases, the market is poised for substantial growth, reflecting the ongoing challenges associated with this disease.

Restraints in the Global Endometrial Cancer Market

A notable challenge facing the global endometrial cancer market is the significant expense associated with treatment and the lack of accessibility to healthcare services, particularly in underdeveloped areas. The financial burden of treatments, such as surgeries, chemotherapy, and radiation therapy, can be quite high, preventing many patients from receiving the necessary care. This situation is exacerbated for individuals with limited health insurance coverage or insufficient financial resources, leading to disparities in treatment options and hindering the overall management of the disease. Ensuring equitable access to affordable care remains a critical issue within the market.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is currently experiencing a dynamic shift characterized by robust collaborations and strategic partnerships between pharmaceutical companies and research institutions. This synergy is focused on expediting drug development and enhancing clinical trial efficiency, which is critical for bringing innovative treatments to market. As a result, there is a growing emphasis on improved diagnostics and the introduction of novel therapies designed to tailor treatment to individual patient needs. These advancements are anticipated to significantly enhance patient outcomes, driving demand for effective solutions in the endometrial cancer space and ultimately transforming the landscape of cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2026-2033)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2026-2033)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations